cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30499696
title: Impact of perioperative platelet counts and IL-6 on wound healing outcomes after thoracoscopic lung cancer surgery

description: Wound healing complications remain significant concerns following thoracoscopic surgery for lung cancer. Perioperative hematological indicators, particularly platelet counts and inflammatory markers, are crucial factors influencing wound healing. Given these gaps, we retrospectively investigated the effect of these indicators on postoperative wound healing outcomes in lung cancer surgery. We conducted a retrospective analysis of 200 patients who underwent thoracoscopic surgery for lung cancer. We assessed platelet counts, IL-6, IL-10, TNF-α, and other hematological markers. Patients were stratified by platelet counts into high and low groups. Correlations between these hematological parameters and clinical outcomes, including intraoperative blood loss, hospitalization duration, and wound healing status, were analysed. Higher perioperative platelet counts were significantly associated with reduced intraoperative bleeding (<i>p</i> = 0.015) and shorter hospital stays (<i>p</i> = 0.019). The high platelet count group showed better Activities of Daily Living (ADL) scores three days post-surgery (<i>p</i> &lt; 0.01). Elevated IL-6 levels preoperatively correlated with adverse wound healing outcomes (<i>p</i> &lt; 0.05). Logistic regression analysis indicated that elevated IL-6 was a predictive marker for poor wound healing (OR 1.30, 95% CI 1.15–1.48). Other markers, including IL-10 and TNF-α, were elevated postoperatively in the low platelet count group, indicating a heightened inflammatory response. Perioperative platelet counts and inflammatory markers, particularly IL-6, significantly influence wound healing in lung cancer surgery. Higher platelet counts were associated with better early postoperative outcomes, while elevated IL-6 levels predict adverse wound healing events. Preoperative IL-6 screening could flag patients who benefit from intensified anti-inflammatory care; multicentre trials with longer follow-up are warranted.
DOI: 10.6084/m9.figshare.30499696.v1
title: Impact of perioperative platelet counts and IL-6 on wound healing outcomes after thoracoscopic lung cancer surgery

description: Wound healing complications remain significant concerns following thoracoscopic surgery for lung cancer. Perioperative hematological indicators, particularly platelet counts and inflammatory markers, are crucial factors influencing wound healing. Given these gaps, we retrospectively investigated the effect of these indicators on postoperative wound healing outcomes in lung cancer surgery. We conducted a retrospective analysis of 200 patients who underwent thoracoscopic surgery for lung cancer. We assessed platelet counts, IL-6, IL-10, TNF-α, and other hematological markers. Patients were stratified by platelet counts into high and low groups. Correlations between these hematological parameters and clinical outcomes, including intraoperative blood loss, hospitalization duration, and wound healing status, were analysed. Higher perioperative platelet counts were significantly associated with reduced intraoperative bleeding (<i>p</i> = 0.015) and shorter hospital stays (<i>p</i> = 0.019). The high platelet count group showed better Activities of Daily Living (ADL) scores three days post-surgery (<i>p</i> &lt; 0.01). Elevated IL-6 levels preoperatively correlated with adverse wound healing outcomes (<i>p</i> &lt; 0.05). Logistic regression analysis indicated that elevated IL-6 was a predictive marker for poor wound healing (OR 1.30, 95% CI 1.15–1.48). Other markers, including IL-10 and TNF-α, were elevated postoperatively in the low platelet count group, indicating a heightened inflammatory response. Perioperative platelet counts and inflammatory markers, particularly IL-6, significantly influence wound healing in lung cancer surgery. Higher platelet counts were associated with better early postoperative outcomes, while elevated IL-6 levels predict adverse wound healing events. Preoperative IL-6 screening could flag patients who benefit from intensified anti-inflammatory care; multicentre trials with longer follow-up are warranted.
DOI: 10.6084/m9.figshare.28587013
title: Understanding East-West differences in subsolid nodules: prevalence and overdiagnosis implications in lung cancer screening

description: Owing to the widespread opportunistic LDCT screening leading to increased overdiagnosis in Asian countries, such as South Korea, mainland China, and Taiwan, this study seeks to analyze the divergence in SSN prevalence between Eastern and Western nations, focusing on the influence of SSN on the growing overdiagnosis trend, notably among females. This retrospective study collected data from 4166 participants who underwent baseline LDCT in a hospital-based cohort between January 2014 and August 2021. Clinical parameters, including age, sex, lung imaging reporting and data system (Lung-RADS) categories, smoking history, pack-year dose, and SSN characteristics, were extracted from electronic medical records. Additionally, a narrative review and pooled analysis integrated relevant published studies on the prevalence of subsolid nodules and sex disparities. The study encompassed 4166 participants, with females accounting for 49.3% and males for 50.7%, with a mean age of 53.38 ± 10.89. The prevalence of SSNs was significantly higher in females (20.1%) than in males (12.6%). Pooled analysis across seven studies revealed a significantly higher prevalence of SSN in Eastern countries (12.6%) compared to the prevalence in Western countries (3.6%) (test for subgroup differences: <i>p</i> &lt; 0.01; I<sup>2</sup> = 100%). Additionally, a notable sex difference was observed in the prevalence of SSNs (risk ratio = 0.489, 95% CI: 0.301–0.796, <i>p</i> &lt; 0.01; reference group: male group). Apart from differences in clinical management and health literacy regarding SSNs between Eastern and Western countries, the high prevalence of SSNs in Asian nations, particularly among females, significantly contributes to the issue of overdiagnosis in opportunistic lung cancer screening in Asian countries. Tailored sex-specific strategies and risk prediction models are essential for effective screening optimization.
DOI: 10.6084/m9.figshare.28587013.v1
title: Understanding East-West differences in subsolid nodules: prevalence and overdiagnosis implications in lung cancer screening

description: Owing to the widespread opportunistic LDCT screening leading to increased overdiagnosis in Asian countries, such as South Korea, mainland China, and Taiwan, this study seeks to analyze the divergence in SSN prevalence between Eastern and Western nations, focusing on the influence of SSN on the growing overdiagnosis trend, notably among females. This retrospective study collected data from 4166 participants who underwent baseline LDCT in a hospital-based cohort between January 2014 and August 2021. Clinical parameters, including age, sex, lung imaging reporting and data system (Lung-RADS) categories, smoking history, pack-year dose, and SSN characteristics, were extracted from electronic medical records. Additionally, a narrative review and pooled analysis integrated relevant published studies on the prevalence of subsolid nodules and sex disparities. The study encompassed 4166 participants, with females accounting for 49.3% and males for 50.7%, with a mean age of 53.38 ± 10.89. The prevalence of SSNs was significantly higher in females (20.1%) than in males (12.6%). Pooled analysis across seven studies revealed a significantly higher prevalence of SSN in Eastern countries (12.6%) compared to the prevalence in Western countries (3.6%) (test for subgroup differences: <i>p</i> &lt; 0.01; I<sup>2</sup> = 100%). Additionally, a notable sex difference was observed in the prevalence of SSNs (risk ratio = 0.489, 95% CI: 0.301–0.796, <i>p</i> &lt; 0.01; reference group: male group). Apart from differences in clinical management and health literacy regarding SSNs between Eastern and Western countries, the high prevalence of SSNs in Asian nations, particularly among females, significantly contributes to the issue of overdiagnosis in opportunistic lung cancer screening in Asian countries. Tailored sex-specific strategies and risk prediction models are essential for effective screening optimization.
DOI: 10.6084/m9.figshare.30438177
title: Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials

description: This study aims to evaluate the efficacy and safety of empagliflozin in acute myocardial infarction (AMI) treatment by synthesizing evidence from published randomized controlled trials (RCTs). PubMed, Web of Science, Embase, and Cochrane databases were thoroughly retrieved from inception to November 30, 2024, to identify eligible RCTs comparing empagliflozin with placebo in AMI treatment. The Cochrane Risk of Bias tool was leveraged to detect potential bias. The robustness of the results was examined <i>via</i> sensitivity analyses. Publication bias was evaluated <i>via</i> funnel plots and Egger’s test. Data from 9 RCTs involving 7,237 AMI patients were analyzed. Meta-analysis revealed that empagliflozin significantly reduced the total hospitalization rate for heart failure (HF) in AMI patients in comparison to placebo (relative risk [RR] = 0.70, 95% confidence interval [CI] = 0.57–0.85). Additionally, empagliflozin significantly improved their ejection fraction (EF) (standard mean difference [SMD] = 1.01, 95% CI = 0.63–1.38), left ventricular global longitudinal strain (LVGLS) (SMD = −0.27, 95% CI = −0.48 to −0.06), body weight (SMD = −0.80, 95% CI = −1.15 to −0.45), and systolic blood pressure (SBP) (SMD = −0.54, 95% CI = −0.88 to −0.20). Statistically significant differences were not noted in other parameters (all <i>p</i> &gt; 0.05). The incidence of adverse events (AEs), such as hepatic dysfunction, contrast-induced nephropathy, and urinary tract infections, did not differ significantly across groups (all <i>p</i> &gt; 0.05). The GRADE rating indicated the evidence for HF hospitalization rate and body weight was of high certainty. Empagliflozin lowers the total hospitalization rate for HF in AMI patients and significantly improves EF, LVGLS, body weight, and SBP without raising the likelihood of AEs. This study aims to shed light on the efficacy and safety of empagliflozin in AMI treatment by synthesizing evidence from published randomized controlled trials (RCTs).Empagliflozin reduces the total hospitalization rate for HF in AMI patients and significantly improves EF, LVGLS, body weight, and SBP without raising the likelihood of AEs. This study aims to shed light on the efficacy and safety of empagliflozin in AMI treatment by synthesizing evidence from published randomized controlled trials (RCTs). Empagliflozin reduces the total hospitalization rate for HF in AMI patients and significantly improves EF, LVGLS, body weight, and SBP without raising the likelihood of AEs.
DOI: 10.6084/m9.figshare.30438177.v1
title: Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials

description: This study aims to evaluate the efficacy and safety of empagliflozin in acute myocardial infarction (AMI) treatment by synthesizing evidence from published randomized controlled trials (RCTs). PubMed, Web of Science, Embase, and Cochrane databases were thoroughly retrieved from inception to November 30, 2024, to identify eligible RCTs comparing empagliflozin with placebo in AMI treatment. The Cochrane Risk of Bias tool was leveraged to detect potential bias. The robustness of the results was examined <i>via</i> sensitivity analyses. Publication bias was evaluated <i>via</i> funnel plots and Egger’s test. Data from 9 RCTs involving 7,237 AMI patients were analyzed. Meta-analysis revealed that empagliflozin significantly reduced the total hospitalization rate for heart failure (HF) in AMI patients in comparison to placebo (relative risk [RR] = 0.70, 95% confidence interval [CI] = 0.57–0.85). Additionally, empagliflozin significantly improved their ejection fraction (EF) (standard mean difference [SMD] = 1.01, 95% CI = 0.63–1.38), left ventricular global longitudinal strain (LVGLS) (SMD = −0.27, 95% CI = −0.48 to −0.06), body weight (SMD = −0.80, 95% CI = −1.15 to −0.45), and systolic blood pressure (SBP) (SMD = −0.54, 95% CI = −0.88 to −0.20). Statistically significant differences were not noted in other parameters (all <i>p</i> &gt; 0.05). The incidence of adverse events (AEs), such as hepatic dysfunction, contrast-induced nephropathy, and urinary tract infections, did not differ significantly across groups (all <i>p</i> &gt; 0.05). The GRADE rating indicated the evidence for HF hospitalization rate and body weight was of high certainty. Empagliflozin lowers the total hospitalization rate for HF in AMI patients and significantly improves EF, LVGLS, body weight, and SBP without raising the likelihood of AEs. This study aims to shed light on the efficacy and safety of empagliflozin in AMI treatment by synthesizing evidence from published randomized controlled trials (RCTs).Empagliflozin reduces the total hospitalization rate for HF in AMI patients and significantly improves EF, LVGLS, body weight, and SBP without raising the likelihood of AEs. This study aims to shed light on the efficacy and safety of empagliflozin in AMI treatment by synthesizing evidence from published randomized controlled trials (RCTs). Empagliflozin reduces the total hospitalization rate for HF in AMI patients and significantly improves EF, LVGLS, body weight, and SBP without raising the likelihood of AEs.
DOI: 10.15468/dl.2ebhmg
title: Occurrence Download

description: A dataset containing 446 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Specimen",
 "OccurrenceStatus is Present",
 "TaxonKey is Panaeolus antillarum"
 ]
}

 The dataset includes 446 records from 53 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003095-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29978526
title: The effect of probiotics on weight management in patients with severe obesity undergoing metabolic and bariatric surgery: a systematic review and meta-analysis

description: Although metabolic and bariatric surgery (MBS) remains an effective intervention for severe obesity, postoperative weight regain persists as a significant clinical challenge. Probiotics have emerged as a potential adjunct therapy to optimize outcomes, but their efficacy in weight management remains controversial. This meta-analysis evaluates the effect of probiotics supplementation on weight management in patients following MBS. A comprehensive search strategy was executed across four databases (PubMed, Embase, Scopus and Cochrane Library) from inception to April 10th, 2025. Inclusion criteria encompassed randomized controlled trials comparing probiotics with placebo in patients with severe obesity undergoing MBS. Primary outcomes including percent excess weight loss (%EWL), postoperative body mass index (BMI), and BMI reduction. Data were pooled using the random-effects model. A total of 13 trials included 693 patients were finally analyzed in the meta-analysis. Pooled analysis demonstrated no significant difference in %EWL (MD 0.39, 95% CI −1.90 to 2.68, I<sup>2</sup>=43%), postoperative BMI (MD 0.07, 95% CI −0.21 to 0.35, I<sup>2</sup>=26%), and BMI reduction (MD −0.05, 95% CI −0.53 to 0.44, I<sup>2</sup>=60%) between probiotics and control groups. Subgroup analyses stratified by surgery type, probiotic formulation and treatment duration similarly revealed no clinically meaningful effects. Current evidence does not support the routine use of probiotics for enhancing weight loss after MBS, regardless of surgical technique and treatment duration. Further large-scale trials standardizing strains, dosages, and outcome metrics are warranted.
DOI: 10.6084/m9.figshare.29978526.v1
title: The effect of probiotics on weight management in patients with severe obesity undergoing metabolic and bariatric surgery: a systematic review and meta-analysis

description: Although metabolic and bariatric surgery (MBS) remains an effective intervention for severe obesity, postoperative weight regain persists as a significant clinical challenge. Probiotics have emerged as a potential adjunct therapy to optimize outcomes, but their efficacy in weight management remains controversial. This meta-analysis evaluates the effect of probiotics supplementation on weight management in patients following MBS. A comprehensive search strategy was executed across four databases (PubMed, Embase, Scopus and Cochrane Library) from inception to April 10th, 2025. Inclusion criteria encompassed randomized controlled trials comparing probiotics with placebo in patients with severe obesity undergoing MBS. Primary outcomes including percent excess weight loss (%EWL), postoperative body mass index (BMI), and BMI reduction. Data were pooled using the random-effects model. A total of 13 trials included 693 patients were finally analyzed in the meta-analysis. Pooled analysis demonstrated no significant difference in %EWL (MD 0.39, 95% CI −1.90 to 2.68, I<sup>2</sup>=43%), postoperative BMI (MD 0.07, 95% CI −0.21 to 0.35, I<sup>2</sup>=26%), and BMI reduction (MD −0.05, 95% CI −0.53 to 0.44, I<sup>2</sup>=60%) between probiotics and control groups. Subgroup analyses stratified by surgery type, probiotic formulation and treatment duration similarly revealed no clinically meaningful effects. Current evidence does not support the routine use of probiotics for enhancing weight loss after MBS, regardless of surgical technique and treatment duration. Further large-scale trials standardizing strains, dosages, and outcome metrics are warranted.
DOI: 10.6084/m9.figshare.30928034
title: Efficacy and safety of remimazolam for sedation during gynaecologic procedures: a systematic review and meta-analysis

description: The efficacy of remimazolam compared to propofol for sedation during gynaecologic procedures remains unknown, due to the increased severity of pain associated with these procedures. Therefore, a systematic review and meta-analysis was conducted to address this issue. The protocol has been registered with PROSPERO, number CRD42024511475. Medline/PubMed, Cochrane Library, Embase, Scopus and Web of Science were searched to identify randomized controlled trials (RCTs) covering the period up to 10 January 2025. The primary outcomes comprised the success rate of sedation and the incidence of body movement. Secondary outcomes included recovery time and incidence of adverse effects (i.e. hypotension, bradycardia, respiratory depression, postoperative nausea and vomiting (PONV), dizziness, hiccup and injection pain). Nine RCTs (1129 patients) were included in this meta-analysis. There were no significant differences for the success rate of sedation (RR = 0.98, 95% confidence interval (CI) 0.96–1.00) or the incidence of body movement (RR = 1.03, 95% CI 0.49–2.14). Remimazolam had a lower incidence of adverse effects, including hypotension (RR = 0.21, 95% CI 0.11–0.41), bradycardia (RR = 0.12, 95% CI 0.02–0.97), respiratory depression (RR = 0.30, 95% CI 0.15–0.61), injection pain (RR = 0.06, 95% CI 0.02–0.17) and dizziness (RR = 0.29, 95% CI 0.10–0.82). However, remimazolam increased the incidence of hiccup (RR = 10.16, 95% CI 2.48–41.61). No significant differences were found regarding the recovery time (MD = 1.58, 95% CI −0.20 to 3.35) or the incidence of PONV (RR = 0.68, 95% CI 0.15–3.05). In gynaecologic procedures, remimazolam has comparable efficacy to propofol in the success rate of sedation and the incidence of body movement, while exhibiting superior respiratory and cardiovascular safety profiles. These findings should be cautiously generalized to other populations, and warrant further validation. First systematic review and meta-analysis to assess the efficacy and safety of remimazolam for sedation during gynaecologic procedures.No significant differences were found in the success rate of sedation or the incidence of body movement between remimazolam and propofol for sedation during gynaecologic procedures.Remimazolam had a lower incidence of adverse effects than propofol for sedation during gynaecologic procedures. First systematic review and meta-analysis to assess the efficacy and safety of remimazolam for sedation during gynaecologic procedures. No significant differences were found in the success rate of sedation or the incidence of body movement between remimazolam and propofol for sedation during gynaecologic procedures. Remimazolam had a lower incidence of adverse effects than propofol for sedation during gynaecologic procedures.
DOI: 10.6084/m9.figshare.30928034.v1
title: Efficacy and safety of remimazolam for sedation during gynaecologic procedures: a systematic review and meta-analysis

description: The efficacy of remimazolam compared to propofol for sedation during gynaecologic procedures remains unknown, due to the increased severity of pain associated with these procedures. Therefore, a systematic review and meta-analysis was conducted to address this issue. The protocol has been registered with PROSPERO, number CRD42024511475. Medline/PubMed, Cochrane Library, Embase, Scopus and Web of Science were searched to identify randomized controlled trials (RCTs) covering the period up to 10 January 2025. The primary outcomes comprised the success rate of sedation and the incidence of body movement. Secondary outcomes included recovery time and incidence of adverse effects (i.e. hypotension, bradycardia, respiratory depression, postoperative nausea and vomiting (PONV), dizziness, hiccup and injection pain). Nine RCTs (1129 patients) were included in this meta-analysis. There were no significant differences for the success rate of sedation (RR = 0.98, 95% confidence interval (CI) 0.96–1.00) or the incidence of body movement (RR = 1.03, 95% CI 0.49–2.14). Remimazolam had a lower incidence of adverse effects, including hypotension (RR = 0.21, 95% CI 0.11–0.41), bradycardia (RR = 0.12, 95% CI 0.02–0.97), respiratory depression (RR = 0.30, 95% CI 0.15–0.61), injection pain (RR = 0.06, 95% CI 0.02–0.17) and dizziness (RR = 0.29, 95% CI 0.10–0.82). However, remimazolam increased the incidence of hiccup (RR = 10.16, 95% CI 2.48–41.61). No significant differences were found regarding the recovery time (MD = 1.58, 95% CI −0.20 to 3.35) or the incidence of PONV (RR = 0.68, 95% CI 0.15–3.05). In gynaecologic procedures, remimazolam has comparable efficacy to propofol in the success rate of sedation and the incidence of body movement, while exhibiting superior respiratory and cardiovascular safety profiles. These findings should be cautiously generalized to other populations, and warrant further validation. First systematic review and meta-analysis to assess the efficacy and safety of remimazolam for sedation during gynaecologic procedures.No significant differences were found in the success rate of sedation or the incidence of body movement between remimazolam and propofol for sedation during gynaecologic procedures.Remimazolam had a lower incidence of adverse effects than propofol for sedation during gynaecologic procedures. First systematic review and meta-analysis to assess the efficacy and safety of remimazolam for sedation during gynaecologic procedures. No significant differences were found in the success rate of sedation or the incidence of body movement between remimazolam and propofol for sedation during gynaecologic procedures. Remimazolam had a lower incidence of adverse effects than propofol for sedation during gynaecologic procedures.